Medtronic plc · News & developments
Medtronic Secures U.S. Clearance for LigaSure Instrument on Hugo Robotic Platform
Medtronic announced that the U.S. Food and Drug Administration cleared its LigaSure RAS Maryland jaw instrument for use on the Hugo robotic-assisted surgery system. Powered exclusively through the Valleylab FT10 energy platform, the instrument seals and cuts vessels, thick tissue, and lymphatics up to 7 mm in diameter in roughly two seconds. The company previously introduced the instrument on Hugo in Europe in 2025 under CE Mark.
Why this matters
Robotic platforms are capital equipment loss-leaders without high-margin consumable attachments. Intuitive Surgical built its economic moat by pairing multi-port da Vinci arms with recurring instrument purchases that lock hospital operating rooms into its catalog. Medtronic is deploying its legacy surgical scale to fight back, migrating LigaSure—a vessel-sealing line used across 45 million open and laparoscopic cases—onto Hugo to give familiar surgeons fewer reasons to stick with rival consoles. The strategic bottleneck remains regulatory clearance breadth. In the United States, Hugo is restricted to urologic procedures, meaning this cleared instrument cannot yet generate consumable revenue across high-volume general and gynecologic soft-tissue surgeries where LigaSure built its reputation. Until the FDA signs off on those pending indications, the instrument primarily serves as an incremental incentive for hospital purchasing committees evaluating multi-port robotic alternatives rather than an immediate revenue engine.